Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes.

Grace RF, Shimano KA, Bhat R, Neunert C, Bussel JB, Klaassen RJ, Lambert MP, Rothman JA, Breakey VR, Hege K, Bennett CM, Rose MJ, Haley KM, Buchanan GR, Geddis A, Lorenzana A, Jeng M, Pastore YD, Crary SE, Neier M, Neufeld EJ, Neu N, Forbes PW, Despotovic JM.

Am J Hematol. 2019 Apr 3. doi: 10.1002/ajh.25479. [Epub ahead of print]

PMID:
30945320
2.

More than one pathway: novel treatment for ITP.

Neunert CE, Lambert MP.

Blood. 2019 Feb 14;133(7):629-630. doi: 10.1182/blood-2018-12-892778. No abstract available.

PMID:
30765496
3.

Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia.

Neunert CE.

Hamostaseologie. 2019 Jan 15. doi: 10.1055/s-0038-1676129. [Epub ahead of print]

PMID:
30646404
4.

Maintenance rituximab for relapsing thrombotic thrombocytopenic purpura: a case report.

Saleem R, Rogers ZR, Neunert C, George JN.

Transfusion. 2019 Mar;59(3):921-926. doi: 10.1111/trf.15093. Epub 2018 Dec 12.

PMID:
30548440
5.

Autoimmune hemolytic anemia and immune thrombocytopenia following hematopoietic stem cell transplant: A critical review of the literature.

Neunert CE, Despotovic JM.

Pediatr Blood Cancer. 2019 Apr;66(4):e27569. doi: 10.1002/pbc.27569. Epub 2018 Dec 10. Review.

PMID:
30537439
6.

Evidence-based management of immune thrombocytopenia: ASH guideline update.

Neunert CE, Cooper N.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):568-575. doi: 10.1182/asheducation-2018.1.568. Review.

PMID:
30504359
7.

MIR-144-mediated NRF2 gene silencing inhibits fetal hemoglobin expression in sickle cell disease.

Li B, Zhu X, Ward CM, Starlard-Davenport A, Takezaki M, Berry A, Ward A, Wilder C, Neunert C, Kutlar A, Pace BS.

Exp Hematol. 2019 Feb;70:85-96.e5. doi: 10.1016/j.exphem.2018.11.002. Epub 2018 Nov 6.

PMID:
30412705
8.

Neonatal ECMO.

Van Ommen CH, Neunert CE, Chitlur MB.

Front Med (Lausanne). 2018 Oct 25;5:289. doi: 10.3389/fmed.2018.00289. eCollection 2018. Review.

9.

Intravenous Immunoglobulin Versus Anti-D Immunoglobulin: When Better Treatment May Not Be the Best Treatment.

O'Brien SH, Despotovic JM, Neunert CE.

J Pediatr. 2019 Jan;204:11-13. doi: 10.1016/j.jpeds.2018.08.062. Epub 2018 Sep 28. No abstract available.

PMID:
30274924
10.

Physician decision making in selection of second-line treatments in immune thrombocytopenia in children.

Grace RF, Despotovic JM, Bennett CM, Bussel JB, Neier M, Neunert C, Crary SE, Pastore YD, Klaassen RJ, Rothman JA, Hege K, Breakey VR, Rose MJ, Shimano KA, Buchanan GR, Geddis A, Haley KM, Lorenzana A, Thompson A, Jeng M, Neufeld EJ, Brown T, Forbes PW, Lambert MP.

Am J Hematol. 2018 Jul;93(7):882-888. doi: 10.1002/ajh.25110. Epub 2018 May 6.

PMID:
29659042
11.

Management of newly diagnosed immune thrombocytopenia: can we change outcomes?

Neunert CE.

Blood Adv. 2017 Nov 14;1(24):2295-2301. doi: 10.1182/bloodadvances.2017009860. eCollection 2017 Nov 14. Review. Erratum in: Blood Adv. 2018 Aug 14;2(15):1817.

12.

Management of newly diagnosed immune thrombocytopenia: can we change outcomes?

Neunert CE.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):400-405. doi: 10.1182/asheducation-2017.1.400. Review. Erratum in: Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):584.

13.

Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants.

Bennett CM, Neunert C, Grace RF, Buchanan G, Imbach P, Vesely SK, Kuhne T.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26736. Epub 2017 Aug 9.

PMID:
28792679
14.

Patterns and influences in health-related quality of life in children with immune thrombocytopenia: A study from the Dallas ITP Cohort.

Flores A, Klaassen RJ, Buchanan GR, Neunert CE.

Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26405. Epub 2017 Jan 23.

PMID:
28111877
15.

Second-line therapies in immune thrombocytopenia.

Grace RF, Neunert C.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):698-706. Review.

16.

Controversies in the treatment of immune thrombocytopenia.

Cuker A, Cines DB, Neunert CE.

Curr Opin Hematol. 2016 Sep;23(5):479-85. doi: 10.1097/MOH.0000000000000270. Review.

PMID:
27380558
17.

Community Health Workers as Support for Sickle Cell Care.

Hsu LL, Green NS, Donnell Ivy E, Neunert CE, Smaldone A, Johnson S, Castillo S, Castillo A, Thompson T, Hampton K, Strouse JJ, Stewart R, Hughes T, Banks S, Smith-Whitley K, King A, Brown M, Ohene-Frempong K, Smith WR, Martin M.

Am J Prev Med. 2016 Jul;51(1 Suppl 1):S87-98. doi: 10.1016/j.amepre.2016.01.016.

18.

Determining Adherence to Quality Indicators in Sickle Cell Anemia Using Multiple Data Sources.

Neunert CE, Gibson RW, Lane PA, Verma-Bhatnagar P, Barry V, Zhou M, Snyder A.

Am J Prev Med. 2016 Jul;51(1 Suppl 1):S24-30. doi: 10.1016/j.amepre.2016.02.011.

19.

Refractory autoimmune disease: an overview of when first-line therapy is not enough.

Neunert C, Farah R, Yacobovich J, Neufeld E.

Semin Hematol. 2016 Apr;53 Suppl 1:S35-8. doi: 10.1053/j.seminhematol.2016.04.011. Epub 2016 Apr 7. Review.

PMID:
27312162
20.

Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.

Neunert C, Despotovic J, Haley K, Lambert MP, Nottage K, Shimano K, Bennett C, Klaassen R, Stine K, Thompson A, Pastore Y, Brown T, Forbes PW, Grace RF; Pediatric ITP Consortium of North America (ICON).

Pediatr Blood Cancer. 2016 Aug;63(8):1407-13. doi: 10.1002/pbc.26003. Epub 2016 May 2.

Supplemental Content

Loading ...
Support Center